FDA approves sensor, mobile app designed to better control asthma, COPD
MADISON, Wis. — Propeller Health, the FDA-cleared digital health solution for chronic respiratory disease, earlier this week announced that the Food and Drug Administration granted 510(k) clearance to market its latest generation of the Propeller platform, including a new sensor.
“Our goal is to minimize or eliminate exacerbations — that drives everything we do. Key to that, particularly as we move deeper into COPD, is optimizing both the patient and provider experience on Propeller,” stated David Van Sickle, CEO of Propeller Health. “We remain focused on building ever better tools to passively collect timely data about inhaled medication use, provide people with coaching and guidance that is relevant, personalized and actionable, and make care teams more efficient through new opportunities to intervene.”
Propeller is a digital therapeutic designed to help patients and their physicians better understand and control asthma, COPD and other respiratory disease to reduce preventable emergency room visits and hospitalizations. With a combination of sensors, mobile apps and analytics, the system encourages adherence to maintenance therapy and remotely monitors use of rescue medications to facilitate early intervention and avoid exacerbations.
Under the new clearance, the Propeller system can now be used to help predict exacerbations in patients with asthma and COPD. By comparing Metered-Dose Inhaler use to a patient’s baseline and the clinical guidelines, Propeller alerts care teams to people who do not have their disease under control, or who may be worsening and heading to an exacerbation.
The system can now also be used to reduce the frequency of respiratory health symptoms and exacerbations by increasing adherence to medications through feedback, such as reminders, notifications and self-management education. Propeller’s automated, real-time coaching educates users about how best to manage their disease, recognize symptoms and avoid triggers. For the first time, that coaching can include inhaler technique — a major barrier to the optimal use of inhaled medications — using information captured during the normal course of use.
The latest sensor is 30% smaller and features a new collar that removes the need for adapter caps, and support for Bluetooth Low Energy which eliminates charging, increasing battery life to over 18 months.
Propeller is designed for healthcare providers, health plans, employers, and other population health management organizations seeking ways to reduce utilization through adherence, patient engagement and remote monitoring.
Beiersdorf continues on growth path in Q1
HAMBURG, Germany — Beiersdorf, whose brands include Nivea and Eucerin, announced that it is “very satisfied” with its first quarter business performance as the consumer business segment posted a 6.3% boost in organic sales during the quarter.
“We are very satisfied with our business performance in the first three months. We continued the company’s steady upward trend, delivered strong sales growth and continued to gain market share in our relevant markets and key categories,” stated Stefan Heidenreich, CEO of Beiersdorf AG.
During the quarter, the company delivered organic sales growth of 6.7%. In nominal terms, sales increased by 1.2% from €1.577 billion to €1.596 billion.
The consumer business segment, which includes the Nivea, Eucerin and La Prairie brands, recorded organic sales growth of 6.3% in the first quarter of the year. In nominal terms, sales increased by 0.4%, from €1.318 billion to €1.323 billion. The key drivers underlying the strong sales growth, according to the company, were the group’s healthy performance in emerging markets and positive growth rates in the saturated European markets.
Nivea delivered 7.6% sales growth, Eucerin 10.3%, and La Prairie 3.4%, the company stated. In looking at organic sales growth by region, North America continued to develop with 7.5% growth.
Looking to 2014, Beiersdorf is expecting sales growth in the consumer business segment to outperform the market in 2014, at a level of 4% to 6%.
CorePharma launches generic Ritalin
MIDDLESEX, N.J. — CorePharma on Thursday announced the launch of methylphenidate hydrochloride tablets USP, the generic version of Ritalin from Novartis. Methylphenidate is intended for the treatment of narcolepsy and attention deficit disorders.
The drug is available in 5-,10- and 20-mg strengths. Methylphenidate immediate release tablets had U.S. sales of approximately $243 million as of December 2013, according to IMS Data.